QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)

Nurix Therapeutics (NRIX) Stock Forecast, Price & News

$11.01
+0.84 (+8.26%)
(As of 02:48 PM ET)
Compare
Today's Range
$10.14
$11.02
50-Day Range
$8.63
$13.28
52-Week Range
$8.34
$19.91
Volume
150,622 shs
Average Volume
340,786 shs
Market Capitalization
$522.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.75

Nurix Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
172.0% Upside
$29.70 Price Target
Short Interest
Bearish
12.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Nurix Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$28,464 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.24) to ($3.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

773rd out of 983 stocks

Pharmaceutical Preparations Industry

388th out of 486 stocks


NRIX stock logo

About Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Needham Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Needham Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
See More Headlines

NRIX Price History

NRIX Company Calendar

Last Earnings
10/14/2021
Today
6/02/2023
Next Earnings (Estimated)
7/06/2023
Fiscal Year End
11/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRIX
Fax
N/A
Employees
242
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.70
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+192.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
10 Analysts

Profitability

Net Income
$-180,360,000.00
Net Margins
-428.29%
Pretax Margin
-428.29%

Debt

Sales & Book Value

Annual Sales
$38.63 million
Book Value
$6.44 per share

Miscellaneous

Free Float
44,029,000
Market Cap
$482.46 million
Optionable
Not Optionable
Beta
1.69

Key Executives

  • Dr. Arthur T. Sands M.D. (Age 61)
    Ph.D., CEO, Pres & Director
    Comp: $842.47k
  • Mr. Johannes Van Houte (Age 57)
    Chief Financial Officer
    Comp: $606.89k
  • Ms. Stefani A. Wolff (Age 60)
    COO & Exec. VP of Product Devel.
    Comp: $387.25k
  • Dr. Gwenn M. Hansen Ph.D. (Age 52)
    Chief Scientific Officer
    Comp: $723.73k
  • Dr. Christine RingDr. Christine Ring (Age 58)
    Gen. Counsel & Sec.
    Comp: $595.83k
  • Dr. John Kuriyan Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Michael Rapé Ph.D.
    Founder & Member of Scientific Advisory Board
  • Prof. Arthur Weiss M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Howard A. Simon Esq. (Age 64)
    J.D., SPHR, VP of Operations & Corp. Counsel
  • Rita Kwong
    Sr. Accounting Mang.













NRIX Stock - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRIX shares.
View NRIX analyst ratings
or view top-rated stocks.

What is Nurix Therapeutics' stock price forecast for 2023?

10 Wall Street research analysts have issued twelve-month price objectives for Nurix Therapeutics' stock. Their NRIX share price forecasts range from $11.00 to $53.00. On average, they anticipate the company's share price to reach $29.70 in the next year. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for NRIX
or view top-rated stocks among Wall Street analysts.

How have NRIX shares performed in 2023?

Nurix Therapeutics' stock was trading at $10.98 on January 1st, 2023. Since then, NRIX stock has decreased by 7.4% and is now trading at $10.17.
View the best growth stocks for 2023 here
.

When is Nurix Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023.
View our NRIX earnings forecast
.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings data on Thursday, October, 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.02. The company had revenue of $10.25 million for the quarter, compared to analyst estimates of $8.73 million. Nurix Therapeutics had a negative net margin of 428.29% and a negative trailing twelve-month return on equity of 60.17%.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

When did Nurix Therapeutics IPO?

(NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Nurix Therapeutics' stock symbol?

Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.04%), Wasatch Advisors LP (6.69%), Price T Rowe Associates Inc. MD (5.45%), ARK Investment Management LLC (4.72%), State Street Corp (4.71%) and Pictet Asset Management SA (2.24%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff.
View institutional ownership trends
.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nurix Therapeutics' stock price today?

One share of NRIX stock can currently be purchased for approximately $10.17.

How much money does Nurix Therapeutics make?

Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $482.46 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($3.53) on an earnings per share basis.

How many employees does Nurix Therapeutics have?

The company employs 242 workers across the globe.

How can I contact Nurix Therapeutics?

The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com.

This page (NASDAQ:NRIX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -